Oxapex, New Alpha Innovation’s first product, has officially launched in New Zealand.

Agricultural Compounds and Veterinary Medicines (ACVM) in New Zealand approved Oxapex for a Variation Application submission on October 27, 2020. Changes made to the original submission have been accepted and approved.

本公司的电邮信箱于今日起已由 "newaiinfo@newainnovation.com" 变更为 "newaiinfo@newalphainnovation.com"。

本公司的英文名称已由 "New A Innovation Limited" 变更为 "New Alpha Innovation Limited"，自2019 年6 月3 日起生效。此外，公司的中文名称 "新意康医药科技有限公司" 则维持不变。

请知悉是次命名变更是不会影响公司架构以及本公司对外已签署的合同及协议书。

Oxapex®IDX has been added to the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species at FDA.

New Alpha Innovation receives Minor Use Permit (permit to allow supply and minor use of an unregistered veterinary chemical product) from Australian Pesticides and Veterinary Medicines Authority (APVMA) for Oxapex®.

New Alpha Innovation receives approval of new drug registration from Agricultural Compounds and Veterinary Medicines (ACVM) in New Zealand for Oxapex®.